Prospects for an AIDS vaccine

Clinical Medicine

Volumn 3, Issue 3, 2003, Pages 269-272

  McMichael, Andrew ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLADISTICS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PHASE 3 CLINICAL TRIAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINE PRODUCTION; VIRUS MORPHOLOGY;

EID: 0038450135     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.3-3-269     Document Type: Conference Paper

References (32)

1. Gottlieb MS, Schroff R, Schanker HM, Weisman JD et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305:1425-31.
2. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
3. Korber B, Gaschen B, Yusim K, Thakallapally R et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Review. Br Med Bull 2001;58:19-42
4. Connor RI, Korber BT, Graham BS, Hahn BH et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 1998;72:1552-76.
5. Wyatt R, Kwong PD, Desjardins E, Sweet RW et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-11.
6. Kwong PD, Wyatt R, Robinson J, Sweet RW et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-59.
7. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Review. Nature 2001;410:980-7.
8. Wilson JD, Ogg GS, Allen RL, Davis C et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. Aids 2000;14:225-33.
9. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-60.
10. Jin X, Bauer DE, Tuttleton SE, Lewin S et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189:991-8.
11. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991;354:453-9.
12. McMichael A. T cell responses and viral escape. Review. Cell 1998;93:673-6.
13. Carrington M, Nelson GW, Martin MP, Kissner T et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999;283:1748-52.
14. Gao X, Nelson GW, Karacki P, Martin MP et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001;344:1668-75.
15. McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Review. Nat Rev Immunol 2002;2:283-91.
16. Barouch DH, Santra S, Kuroda MJ, Schmitz JE et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001;75:5151-8.
17. Amara RR, Villinger F, Altman JD, Lydy SL et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
18. Shiver JW, Fu TM, Chen L, Casimiro DR et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-5.
19. Rose NF, Marx PA, Luckay A, Nixon DF et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539-49.
20. Rowland-Jones SL, Dong T, Fowke KR, Kimani J et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998;102:1758-65.
21. Webster RG, Askonas BA. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol 1980;10:396-401.
22. Schneider J, Gilbert SC, Blanchard TJ, Hanke T et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
23. Hanke T, Blanchard TJ, Schneider J, Hannan CM et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998;16:439-45.
24. Hanke T, Samuel RV, Blanchard TJ, Neumann VC et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999;73:7524-32.
25. Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 2000;6: 951-5.
26. Mwau et al (submitted).
27. Emini EA. http.//www.retroconference.org/2002/about.htm
28. Burrows SR, Silins SL, Moss DJ, Khanna R et al. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med 1995; 182:1703-15.
29. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415:335-9.
30. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Review. Annu Rev Immunol 1999;17:51-88.
31. Appay V, Papagno L, Spina CA, Hansasuta P et al. Dynamics of T cell responses in HIV infection. J Immunol 2002;168:3660-6.
32. Zinkernagel RM. On immunological memory. Review. Philos Trans R Soc Lond B Biol Sci 2000;355:369-71.